4D Pharma
Leeds
About 4D Pharma
4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D currently has a pipeline of 15 therapeutic programmes covering autoimmune diseases, CNS disorders and cancer; with two programmes in patient trials, and the expectation to initiate another three programmes over the coming twelve months.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $53.9M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jul 2021)
- Ticker: lse:DDDD
- Website: 4dpharmaplc.com
- Phone: +44 1224 900 460
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/4d-pharma-64120 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.